This grant offered by the NIH aims to study the absorption of low molecular weight species in PEG 3350 products among children, particularly focusing on potential adverse events. The research intends to shed light on the effects of PEG 3350 use in pediatric constipation treatment and its possible implications on children’s health. Understanding the absorption of these species is crucial in determining the association between PEG 3350 usage and adverse reactions in the pediatric population. Closing date: Mar 14, 2014.
Opportunity ID: 250023
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-FD-14-002 |
Funding Opportunity Title: | The Use of Polyethylene Glycol in the Pediatric Population (R01) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Consumer Protection Health |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 93.103 — Food and Drug Administration_Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Jan 14, 2014 |
Last Updated Date: | Feb 21, 2014 |
Original Closing Date for Applications: | Feb 28, 2014 |
Current Closing Date for Applications: | Mar 14, 2014 |
Archive Date: | Mar 30, 2014 |
Estimated Total Program Funding: | $225,000 |
Award Ceiling: | $225,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education For profit organizations other than small businesses Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments City or township governments Public housing authorities/Indian housing authorities State governments |
Additional Information on Eligibility: | Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed. |
Additional Information
Agency Name: | Food and Drug Administration |
Description: | The purpose of the proposed study is to better understand the extent of pediatric absorption of low molecular weight species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol). PEG 3350 products are used in the treatment of constipation. These low molecular weight species may be absorbed by children taking PEG 3350 products, potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these species. |
Link to Additional Information: | Full Announcement of RFA-FD-14-001 on NIH Guide for Grants and Contracts |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Lisa Ko
Grants Management Specialist Email:lisa.ko@fda.hhs.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Application deadline date has been changed to 03/14/2014. | Feb 21, 2014 | |
Feb 21, 2014 |
DISPLAYING: Synopsis 2
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-FD-14-002 |
Funding Opportunity Title: | The Use of Polyethylene Glycol in the Pediatric Population (R01) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Consumer Protection Health |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 93.103 — Food and Drug Administration_Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Jan 14, 2014 |
Last Updated Date: | Feb 21, 2014 |
Original Closing Date for Applications: | Feb 28, 2014 |
Current Closing Date for Applications: | Mar 14, 2014 |
Archive Date: | Mar 30, 2014 |
Estimated Total Program Funding: | $225,000 |
Award Ceiling: | $225,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education For profit organizations other than small businesses Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments City or township governments Public housing authorities/Indian housing authorities State governments |
Additional Information on Eligibility: | Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed. |
Additional Information
Agency Name: | Food and Drug Administration |
Description: | The purpose of the proposed study is to better understand the extent of pediatric absorption of low molecular weight species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol). PEG 3350 products are used in the treatment of constipation. These low molecular weight species may be absorbed by children taking PEG 3350 products, potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these species. |
Link to Additional Information: | Full Announcement of RFA-FD-14-001 on NIH Guide for Grants and Contracts |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Lisa Ko
Grants Management Specialist Email:lisa.ko@fda.hhs.gov |
DISPLAYING: Synopsis 1
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-FD-14-002 |
Funding Opportunity Title: | The Use of Polyethylene Glycol in the Pediatric Population (R01) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Consumer Protection Health |
Category Explanation: | – |
Expected Number of Awards: | 1 |
Assistance Listings: | 93.103 — Food and Drug Administration_Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Feb 21, 2014 |
Last Updated Date: | – |
Original Closing Date for Applications: | – |
Current Closing Date for Applications: | Feb 28, 2014 |
Archive Date: | Mar 30, 2014 |
Estimated Total Program Funding: | $225,000 |
Award Ceiling: | $225,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) City or township governments For profit organizations other than small businesses State governments Private institutions of higher education |
Additional Information on Eligibility: | Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed. |
Additional Information
Agency Name: | Food and Drug Administration |
Description: | The purpose of the proposed study is to better understand the extent of pediatric absorption of low molecular weight species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol). PEG 3350 products are used in the treatment of constipation. These low molecular weight species may be absorbed by children taking PEG 3350 products, potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these species. |
Link to Additional Information: | Full Announcement of RFA-FD-14-001 on NIH Guide for Grants and Contracts |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Lisa Ko
Grants Management Specialist Email:lisa.ko@fda.hhs.gov |
Related Documents
There are no related documents on this grant.
Packages
Agency Contact Information: | Lisa Ko Grants Management Specialist Email: lisa.ko@fda.hhs.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
93.103 | PKG00191844 | Jan 21, 2014 | Mar 14, 2014 | View |
Package 1
Mandatory forms
250023 RR_SF424_2_0-2.0.pdf
250023 PHS398_ResearchPlan_2_0-2.0.pdf
250023 PHS398_CoverPageSupplement_2_0-2.0.pdf
250023 RR_Budget_1_3-1.3.pdf
250023 RR_KeyPersonExpanded_2_0-2.0.pdf
250023 RR_OtherProjectInfo_1_3-1.3.pdf
250023 PerformanceSite_2_0-2.0.pdf
Optional forms
250023 PlannedReport-1.0.pdf
250023 PHS398_CumulativeInclusionReport-1.0.pdf
250023 RR_SubawardBudget30_1_3-1.3.pdf